PubMed

Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial.

Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, D'Haens G, Li J, Rosenfeld MR, Kent JD, Pollack PF.

Ann Intern Med. 2007 Jun 19;146(12):829-38. Epub 2007 Apr 30.PMID: 17470824 [PubMed - indexed for MEDLINE]Related articlesFree article

Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.

Behm BW, Bickston SJ.

Cochrane Database Syst Rev. 2008 Jan 23;(1):CD006893. Review.PMID: 18254120 [PubMed - indexed for MEDLINE]Related articles

Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial.

Colombel JF, Sandborn WJ, Rutgeerts P, Kamm MA, Yu AP, Wu EQ, Pollack PF, Lomax KG, Chao J, Mulani PM.

Am J Gastroenterol. 2009 May;104(5):1170-9. Epub 2009 Apr 7.PMID: 19352339 [PubMed - indexed for MEDLINE]Related articles

Maintenance therapy with certolizumab pegol for Crohn's disease.

Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OØ, Hanauer SB, McColm J, Bloomfield R, Sandborn WJ; PRECISE 2 Study Investigators.

N Engl J Med. 2007 Jul 19;357(3):239-50. Erratum in: N Engl J Med. 2007 Sep 27;357(13):1357. PMID: 17634459 [PubMed - indexed for MEDLINE]Related articlesFree article

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.

Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D, Li J, Kent JD, Pollack PF.

Gastroenterology. 2007 Jan;132(1):52-65. Epub 2006 Nov 29.PMID: 17241859 [PubMed - indexed for MEDLINE]Related articles

An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease.

Sandborn WJ, Hanauer S, Loftus EV Jr, Tremaine WJ, Kane S, Cohen R, Hanson K, Johnson T, Schmitt D, Jeche R.

Am J Gastroenterol. 2004 Oct;99(10):1984-9.PMID: 15447761 [PubMed - indexed for MEDLINE]Related articles

Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial.

Hoffman GS, Cid MC, Rendt-Zagar KE, Merkel PA, Weyand CM, Stone JH, Salvarani C, Xu W, Visvanathan S, Rahman MU; Infliximab-GCA Study Group.

Ann Intern Med. 2007 May 1;146(9):621-30.PMID: 17470830 [PubMed - indexed for MEDLINE]Related articlesFree article

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial.

Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, Panaccione R, Wolf D, Pollack P.

Gastroenterology. 2006 Feb;130(2):323-33; quiz 591.PMID: 16472588 [PubMed - indexed for MEDLINE]Related articles

Efficacy and safety of short-term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial.

Hinojosa J, Gomollón F, García S, Bastida G, Cabriada JL, Saro C, Ceballos D, Peñate M, Gassull MA; Spanish Scientific Group on Crohn's Disease and Ulcerative Colitis.

Aliment Pharmacol Ther. 2007 Feb 15;25(4):409-18.PMID: 17269996 [PubMed - indexed for MEDLINE]Related articlesFree article

Infliximab maintenance therapy for fistulizing Crohn's disease.

Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Kamm MA, Korzenik JR, Lashner BA, Onken JE, Rachmilewitz D, Rutgeerts P, Wild G, Wolf DC, Marsters PA, Travers SB, Blank MA, van Deventer SJ.

N Engl J Med. 2004 Feb 26;350(9):876-85.PMID: 14985485 [PubMed - indexed for MEDLINE]Related articlesFree article

Infliximab for induction and maintenance therapy for ulcerative colitis.

Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF.

N Engl J Med. 2005 Dec 8;353(23):2462-76. Erratum in: N Engl J Med. 2006 May 18;354(20):2200. PMID: 16339095 [PubMed - indexed for MEDLINE]Related articlesFree article

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial.

Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, Fischkoff SA, Chartash EK.

Arthritis Rheum. 2004 May;50(5):1400-11.PMID: 15146409 [PubMed - indexed for MEDLINE]Related articlesFree article

Adalimumab: in Crohn's disease.

Plosker GL, Lyseng-Williamson KA.

BioDrugs. 2007;21(2):125-32; discussion 133-4. Review.PMID: 17402796 [PubMed - indexed for MEDLINE]Related articles

CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial.

Sandborn WJ, Feagan BG, Radford-Smith G, Kovacs A, Enns R, Innes A, Patel J.

Gut. 2004 Oct;53(10):1485-93.PMID: 15361500 [PubMed - indexed for MEDLINE]Related articlesFree article

Natalizumab induction and maintenance therapy for Crohn's disease.

Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC, Panaccione R, Sanders M, Schreiber S, Targan S, van Deventer S, Goldblum R, Despain D, Hogge GS, Rutgeerts P; International Efficacy of Natalizumab as Active Crohn's Therapy (ENACT-1) Trial Group; Evaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial Group.

N Engl J Med. 2005 Nov 3;353(18):1912-25.PMID: 16267322 [PubMed - indexed for MEDLINE]Related articlesFree article

Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.

Sandborn WJ, Hanauer SB, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh DG, Panaccione R, Wolf D, Kent JD, Bittle B, Li J, Pollack PF.

Gut. 2007 Sep;56(9):1232-9. Epub 2007 Feb 13.PMID: 17299059 [PubMed - indexed for MEDLINE]Related articlesFree article

Anti-interleukin-12 antibody for active Crohn's disease.

Mannon PJ, Fuss IJ, Mayer L, Elson CO, Sandborn WJ, Present D, Dolin B, Goodman N, Groden C, Hornung RL, Quezado M, Yang Z, Neurath MF, Salfeld J, Veldman GM, Schwertschlag U, Strober W; Anti-IL-12 Crohn's Disease Study Group.

N Engl J Med. 2004 Nov 11;351(20):2069-79. Erratum in: N Engl J Med. 2005 Mar 24;352(12):1276. Yang, Zhiqiong [added]. PMID: 15537905 [PubMed - indexed for MEDLINE]Related articlesFree article

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P; ACCENT I Study Group.

Lancet. 2002 May 4;359(9317):1541-9.PMID: 12047962 [PubMed - indexed for MEDLINE]Related articles

Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).

Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, Fischkoff SA, Chartash EK.

J Rheumatol. 2003 Dec;30(12):2563-71.PMID: 14719195 [PubMed - indexed for MEDLINE]Related articles

Adalimumab maintenance therapy for Crohn's disease with intolerance or lost response to infliximab: an open-label study.

Peyrin-Biroulet L, Laclotte C, Bigard MA.

Aliment Pharmacol Ther. 2007 Mar 15;25(6):675-80.PMID: 17311600 [PubMed - indexed for MEDLINE]Related articlesFree article